- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04072458
A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Michael Hickey
- Phone Number: 832-742-1361
- Email: mhickey@biopathholdings.com
Study Locations
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Recruiting
- Georgia Cancer Center
-
Contact:
- Julie Stiefel
- Phone Number: 706-721-0734
- Email: jstiefel@augusta.edu
-
Principal Investigator:
- Locke J Bryan, MD
-
-
New York
-
Valhalla, New York, United States, 10595
- Recruiting
- New York Medical College / Westchester Medical Center
-
Contact:
- Allyson Pulsoni
- Phone Number: 914-493-6610
- Email: allyson.pulsoni@wmchealth.org
-
Contact:
- Karen Seiter, MD
- Email: karen_seiter@nymc.edu
-
Principal Investigator:
- Karen Seiter, MD
-
-
Tennessee
-
Nashville, Tennessee, United States, 37203
- Terminated
- Sarah Cannon Research Institute/Tennesee Oncology
-
-
Texas
-
Dallas, Texas, United States, 75390
- Recruiting
- University of Texas Southwestern Medical Center
-
Contact:
- Ryan Sabu
- Phone Number: 214-645-9883
- Email: Ryan.Sabu@utsouthwestern.edu
-
Principal Investigator:
- Praveen Ramakrishnan, MD
-
Houston, Texas, United States, 77030
- Terminated
- MD Anderson Cancer Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Adults ≥18 years of age
- Patient has a life expectancy ≥ 3 month
Patient has relapsed or refractory disease Relapsed lymphoma: Relapsed lymphoma is disease that has responded to treatment but then returns.
Refractory lymphoma: Failure to achieve complete response at the end of therapy or progression within 6 months from completion of therapy
Included Diseases
- DLBCL, including transformed lymphoma
- Mantle Cell Lymphoma
- PTCL
- CTCL
- CLL/SLL
- Follicular lymphoma
- Marginal zone lymphoma
- Hodgkin lymphoma (both classical and lymphocyte predominant)
- Waldenströms Macroglobulinemia
- Must has failed or is not a candidate for available therapies with reasonable likelihood of clinical benefit, which includes FDA approved products and standard of care regimens
- Therapy means at least three front lines of therapy including Hematopoeitic Stem Cell Transplant (HSCT and/or Chimeric Antigen Receptor (CAR) T cells, when applicable
- Females must be of non-childbearing potential, surgically sterile, postmenopausal, or practice adequate methods of contraception during the study
- Males must agree to use an adequate method of contraception during the study
- Eastern Cooperative Oncology Group (ECOG) Performance score of 0, 1, or 2
Adequate hepatic and renal functions as defined by:
- Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 times the upper limit of normal (ULN); and
- Total bilirubin ≤1.5 times ULN; and
Estimated glomerular filtration rate (eGFR) of at least 50ml/min. These estimations can be calculated using the following methods:
- Chronic Kidney Disease Epidemiology Collaboration (CKD-Epi) equation
- Cockcroft Gault equation
- Modification of Diet in Renal Disease (MDRD study equation)
- Creatinine clearance estimated by 24-hr urine collection for creatinine clearance
- Recovered from the effects of any prior surgery, radiotherapy, or antineoplastic treatment (with the exception of alopecia), based on Investigator assessment
- Willing and able to provide written informed consent
Exclusion Criteria:
- Active non-hematologic malignancy other than lymphoid malignancies treated with immuno- or chemotherapy within the previous 12 months except active non-melanoma, non-invasive skin cancer will be allowed
- Known, active Central Nervous System (CNS) involvement of disease requiring intrathecal therapy. Note: Patients with a history of CNS disease may be allowed to participate based on at least 1 documented, negative spinal fluid assessment within 28 days prior to Screening
- Patient eligible for high dose chemotherapy and autologous stem cell transplant
- Indolent non-Hodgkin lymphoma (iNHL)
Patients at high risk of Tumor Lysis Syndrome (TLS)
a. Bulky disease i. A unidimensional lesion greater than 10 cm and/or b. Lymphocyte count greater than 25,000 per µL
- Receipt of any anti-cancer therapy within 14 days prior to Cycle 1 Day 1 (C1D1)
- Uncontrolled active, untreated, or progressive infection
- Receipt of any investigational agent or on study treatment within 30 days prior to C1D1
- Females who are pregnant, test positive for pregnancy, or are breast-feeding during the Screening period, or intend to become pregnant or breast-feed during the course of the study or within 30 days after last dose of study drug
- Serious intercurrent medical or psychiatric illness which, in the opinion of the Investigator, would interfere with the ability of the participant to complete the study
- Active hepatitis B infection (based on positive surface antigen [HBsAg]), hepatitis C infection (based on Hepatitis C Virus (HCV) positive antibody [HCV Ab]), or human immunodeficiency virus (HIV-1 or HIV-2, based on positive antibody)
- Presence of concurrent conditions that, in the opinion of the Investigator and/or Medical Monitor, may compromise or interfere with any aspect of study conduct or interpretation of results. This includes, but is not limited to, unstable or uncontrolled angina, New York Heart Association (NYHA) class III or IV congestive heart failure, uncontrolled and sustained hypertension, clinically significant cardiac dysrhythmia or clinically significant baseline EKG abnormality (e.g., QTcF >470 msec)
- Within the past 6 months, has had any of the following: myocardial infarction, unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack
- Uncontrolled seizure disorder
- Unable or unwilling to communicate or cooperate with the Investigator or follow the protocol for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BP1002 monotherapy
L-Bcl-2 Antisense oligonucleotide (BP1002) is given in a sequential, dose escalation design.
Starting dose is 20mg/m^2.
|
There will be 2 planned dose levels, 20, and 40 mg/m^2.
Successive cohorts of eligible patients with will be treated with BP1002.
BP1002 is given as an intravenous infusion, twice weekly, as 8 doses per 28-day cycle.
Cycles may be repeated every 4 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Identify Dose Limiting Toxicity (DLT) of BP1002
Time Frame: 30 days
|
Identify DLT of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria
|
30 days
|
Identify and grade treatment-emergent adverse events (TEAE) of escalating doses of BP1002
Time Frame: 30 days
|
Identify TEAE of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria
|
30 days
|
Determine half-life plasma pharmacokinetics (PK) of BP1002
Time Frame: 30 days
|
Evaluate in vivo PK of BP1002 half-life (t1/2)
|
30 days
|
Identify and grade treatment-emergent laboratory abnormalities of escalating doses of BP1002 by identification and grading of
Time Frame: 30 days
|
Identify and grade treatment-emergent laboratory abnormalities of BP1002 using non-hematologic and hematologic measures per NCI CTCAE criteria
|
30 days
|
Identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) of escalating doses of BP1002
Time Frame: 30 days
|
Collection of 12-lead EKGs at defined intervals to identify conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals)
|
30 days
|
Recommended Phase 2 dose (RP2D) of BP1002
Time Frame: 210 days
|
Determine RP2D by evaluating Maximally Tolerated Dose (MTD) data: Any Dose Limiting Toxicity (DLT) observed will trigger an expansion of a cohort from 3 to 6 patients.
A second DLT at any dose level will identify the Maximum Dose.
The dose below that will be the MTD.
|
210 days
|
Determine plasma pharmacokinetics (PK) of BP1002 using maximum plasma drug concentration
Time Frame: 30 days
|
Evaluate in vivo PK of BP1002 using maximum plasma drug concentration (Cmax)
|
30 days
|
Determine plasma pharmacokinetics (PK) of BP1002 using volume of distribution
Time Frame: 30 days
|
Evaluate in vivo PK of BP1002 volume of distribution (Vd)
|
30 days
|
Determine plasma pharmacokinetics (PK) of BP1002 using elimination rate constant
Time Frame: 30 days
|
Evaluate in vivo PK of BP1002 elimination rate constant
|
30 days
|
Determine pharmacokinetics (PK) of BP1002
Time Frame: 30 days
|
12-lead EKG assessments will be collected and analyzed for conduction and rhythm changes (treatment emergent QTc elevations or other treatment emergent changes in EKG intervals) from those the EKG obtained immediately before the first BP1002 dose, and after BP1002 dose, and will mirror the time points used to collect the plasma PK assessments
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine evidence of tumor response by bone marrow aspirate
Time Frame: 30 days
|
Assess tumor response by evaluating bone marrow aspirate to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th)
|
30 days
|
Determine evidence of tumor response by Complete Blood Count (CBC)
Time Frame: 30 days
|
Assess tumor response by evaluating CBC measurements to determine complete response (CR), partial response (PR), or minor response (MR) using appropriate uniform response criteria as published by Response Evaluation Criteria in Lymphoma (RECIL) 2017, CLL guidelines, and International Workshop on Waldenström's Macroglobulinemia (IWWM 6th)
|
30 days
|
Determine estimates for time to progression (TTP)
Time Frame: 30 days
|
Measured from treatment start date to date of progression by CBC and/or bone marrow aspirate
|
30 days
|
Determine estimates for progression-free survival (PFS)
Time Frame: 30 days
|
Measured from treatment start date to date of progression or death by CBC and/or bone marrow aspirate
|
30 days
|
Determine estimates for event-free survival (EFS)
Time Frame: 30 days
|
Measured from treatment start date to date of progression, death, or change in therapy by CBC and/or bone marrow aspirate
|
30 days
|
Activity of BP1002 on Bcl-2 expression in tumor samples
Time Frame: 30 days
|
Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression using patient blood samples
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Exploratory objective to correlate treatment response with cytogenetic characteristics
Time Frame: 30 days
|
Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression
|
30 days
|
Exploratory objective to correlate treatment response with molecular characteristics
Time Frame: 30 days
|
Flow cytometric assays to determine the effects of BP1002 on Bcl-2 protein expression
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Disease Attributes
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Leukemia, Lymphoid
- Leukemia
- Leukemia, B-Cell
- Chronic Disease
- Lymphoma
- Lymphoma, Mantle-Cell
- Waldenstrom Macroglobulinemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Peripheral
- Lymphoma, T-Cell, Cutaneous
Other Study ID Numbers
- BP1002-101-Lymph
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Follicular Lymphoma
-
Joseph TuscanoNational Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.RecruitingAnn Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
National Cancer Institute (NCI)TerminatedStage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRecurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Memorial Sloan Kettering Cancer CenterFox Chase Cancer Center; Pharmacyclics LLC.TerminatedFollicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIaUnited States
-
Olivia Newton-John Cancer Research InstituteBristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaboratorsRecruitingFollicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IVAustralia
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Massachusetts General HospitalTG TherapeuticsActive, not recruitingLymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2United States
-
Fondazione Italiana Linfomi ONLUSCompletedFollicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3AItaly
-
National Cancer Institute (NCI)Celgene CorporationActive, not recruitingAnn Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingGrade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...United States
Clinical Trials on L-Bcl-2 antisense oligonucleotide
-
Genta IncorporatedCompleted
-
Genta IncorporatedCompleted
-
Brigham and Women's HospitalUnknown
-
Bio-Path Holdings, Inc.RecruitingAcute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia RefractoryUnited States
-
Brigham and Women's HospitalGlaxoSmithKline; Ionis Pharmaceuticals, Inc.Withdrawn
-
Massachusetts General Hospitaln-Lorem FoundationNot yet recruiting
-
ProQR TherapeuticsActive, not recruitingEye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf BlindUnited States, Netherlands, United Kingdom, Germany
-
ProQR TherapeuticsCompletedEye Diseases | Retinitis Pigmentosa | Eye Diseases, Hereditary | Vision Disorders | Retinal Disease | Eye Disorders Congenital | Usher Syndrome Type 2 | Deaf BlindUnited States, Canada, France
-
National Cancer Institute (NCI)CompletedWaldenström MacroglobulinemiaUnited States
-
Isarna Therapeutics GmbHCompletedPrimary Open Angle GlaucomaGermany